Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

AIDS Drugs Slash Risk of Getting HIV in First Place

Pair of studies show minimum 60% drop in infection rate

By Evann Gastaldo, Newser Staff

Posted Jul 13, 2011 6:55 AM CDT | Updated Jul 13, 2011 7:58 AM CDT

(Newser) – The same antiretroviral drugs that treat HIV and AIDS can also be used to cut down the risk of contracting HIV in the first place, two new studies show. The dramatic results are just the latest evidence that AIDS drugs can be effective at prevention... Read full story »

COMMENTS

Read the comment policy

You need to Log in to Newser to comment. Don't have an account yet? Sign up now!

3 comments

A snapshot of the day's best news stories.

View Larger Grid

All Today Yesterday Pick a Date

What's Popular Now on Facebook

Japanese Artist Serves Up Own Cooked Genitals

Rape Conviction Cleared, Thanks to Facebook

Washington Post (Source Grid »)

Health • Science

AIDS • HIV • HIV/AIDS • AIDS prevention • Gilead Sciences • AIDS virus • antiretroviral drug

More Newser Stories

Study Yields Breakthrough in AIDS Treatment

Taking antiretroviral drugs early slashes risk of spreading disease

(NEWSER) - AIDS patients who get treated early with antiretroviral drugs are as much as 96% less likely to pass on the disease to their sexual partners, according to a major new study. An independent review board found the results so persuasive they recommended the findings be released four years ahead of the study’s scheduled end, the Wall Street Journal reports. The breakthrough suggests AIDS patients should be put on the drugs ASAP. More»

At-Home HIV Test Moves Step Closer to Reality

FDA panel gives OraQuick thumbs up; final decision expected later this year

(NEWSER) - About 240,000 HIV carriers in the US are unaware of their infection—and they may soon have a quick and easy way to test for the virus at home. The over-the-counter OraQuick test requires a mouth swab and delivers results in 20 minutes, and though it is likely slightly less accurate than a professionally-administered test, the FDA's advisory panel has determined that the benefits of expanding testing outweigh any risks. The panel’s 17 members voted unanimously in favor of the test yesterday, and the FDA will make a final decision later this year. More»

FDA Panel Backs First Drug to Block HIV

Truvada, made by Gilead Sciences, is for healthy people at risk

(AP) - A panel of federal health advisers has endorsed the first drug shown to prevent HIV infection in healthy people, clearing the way for a potentially landmark approval in the 30-year-old effort against the virus that causes AIDS. In a series of votes, the FDA advisory panel recommended approval of the daily pill Truvada for healthy people who are at high risk of contracting HIV, including gay and bisexual men, and heterosexual couples with one HIV-infected person. More»

Scientists Find HIV's Achilles Heel

Vaccines should target one area, not the entire virus, new research suggests

(NEWSER) - Scientists have made an important breakthrough in HIV research, and we have the stock market to thank. Researchers used random matrix theory, which is also used to analyze stock behavior, to identify a major target for HIV and AIDS drugs—what the Wall Street Journal calls its “Achilles heel.” The research suggests that an HIV vaccine should focus on a few targets, instead of waging a broad war on the virus. Basically, this method is what a small group of patients—who control the virus without medication—known as “elite controllers” do naturally. More»

Since 2001, New HIV Infections Plummeted 25%

Still, some 2.6M were infected in 2009

(NEWSER) - Good news in the fight against AIDS: The annual rate of new HIV infections dropped by almost a quarter between 2001 and 2009, AIDS-related deaths have fallen, and the world has seen “unprecedented advances” in prevention and treatment accessibility, the UN AIDS agency says. Still, the unevenly-spread advancements are highly "fragile," and global targets haven’t been reached. At the end of last year, more than 34 million were living with HIV; some 2.6 million were infected in 2009, the AP reports. More»

NEWS FROM OUR PARTNERS

What is Newser?

Face it: there's too much news. At Newser, we choose the most thought-provoking and entertaining stories from hundreds of US and international sources and reduce them to a headline, picture, and two paragraphs. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »

Partnering with: Slate

View Newser on the mobile website

AIDS Drugs Slash Risk of Getting HIV in First Place

Pair of studies show minimum 60% drop in infection rate

AIDS • HIV • HIV/AIDS • AIDS prevention • Gilead Sciences • AIDS virus • antiretroviral drug

MOST POPULAR STORIES

[ By Views ]

[ By Comments ]

More Newser Stories

Study Yields Breakthrough in AIDS Treatment

Taking antiretroviral drugs early slashes risk of spreading disease

At-Home HIV Test Moves Step Closer to Reality

FDA panel gives OraQuick thumbs up; final decision expected later this year

FDA Panel Backs First Drug to Block HIV

Truvada, made by Gilead Sciences, is for healthy people at risk

Scientists Find HIV's Achilles Heel

Vaccines should target one area, not the entire virus, new research suggests

Since 2001, New HIV Infections Plummeted 25%

Still, some 2.6M were infected in 2009

About Us

Site

Community

Site Maps

Tools

More News

What is Newser?